On October 25, 2021 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809), reported preliminary and unaudited results for the first nine months ended 30 September 2021 (Press release, Evotec, OCT 25, 2021, View Source;announcements/press-releases/p/evotec-provides-preliminary-nine-month-financial-results-6104 [SID1234591925]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Evotec expects revenues from contracts with customers for the first nine months of 2021 to be in the range of € 425 – 435 m; significantly above the € 360.4 m posted in the prior year’s period. Like-for-like growth (excluding Sanofi payments of € 8.6 m in Q1 2020 and negative fx-effects) is expected to be in the range of 24 – 27%
Adjusted Group EBITDA for the first nine months of 2021 is expected to reach € 68 – 72 m, compared to € 76.9 m as of 30 September 2020, affected primarily by planned capacity build-up ahead of imminent production start of J.POD 1 US, Redmond. Like-for-like growth (adjusting for Sanofi and negative fx-effects) is expected to be within a range of 12 – 18%
Evotec expects unpartnered R&D expenses in the period to be between € 41 – 44 m, between € 8 – 11 m higher than in 9M 2020
The expected financial results discussed in this press release are based upon information available to Evotec as of the date hereof. This data is not a comprehensive statement of the Company’s financial results for the nine months ended 30 September 2021, and the closing process and related auditor review have not been completed. During the preparation of Evotec’s comprehensive financial statements adjustments to the preliminary estimated financial information presented herein may be identified, and such changes could be material. There can be no assurance that these estimates will be realised, and these estimates are subject to risks and uncertainties, many of which are not within the Company’s control. The timing of this disclosure is unique to this quarter given the timing of the Company’s application to list on the Nasdaq Global Select Market, and it does not intend to report preliminary results in future quarters. Evotec will issue complete financial results in connection with its 9M conference call on 11 November 2021.